Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin

Abstract

Although exhibiting minimal clinical efficacy at this dose and schedule, DP mediates biological effects that may warrant further evaluation of this histone deacetylase inhibitor in combination with novel-targeted agents in lung cancer patients.